摘要
目的探讨阿托伐他汀钙在慢性心衰合并心律失常患者中的临床疗效。方法94慢性心力衰竭并心律失常患者作为研究对象,根据奇偶数原则分为参考组(n=47)和研究组(n=47)。参考组给予胺碘酮治疗,研究组给予阿托伐他汀钙治疗。比较两组患者临床疗效、血压[收缩压(SBP)、舒张压(DBP)]水平、血脂[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)]变化情况、心功能[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)和左心室舒张末期内径(LVEDD)]。结果研究组治疗总有效率97.87%显著高于参考组的82.98%(P<0.05)。治疗后,研究组SBP为(125.27±3.36)mm Hg(1 mm Hg=0.133 kPa),DBP为(84.32±2.55)mm Hg,均低于参考组的(138.78±5.67)、(97.47±3.63)mm Hg(P<0.05)。治疗后,研究组HDL-C水平高于参考组,LDL-C、TC、TG水平低于参考组(P<0.05)。治疗后,研究组LVEF(56.68±4.28)%、LVESD(42.17±5.45)mm和LVEDD(50.53±3.85)mm均比参考组的(51.19±4.96)%、(45.95±4.77)mm、(54.23±4.41)mm更优(P<0.05)。结论阿托伐他汀钙可以显著提高慢性心力衰竭并心律失常患者的临床治疗效果,同时改善心功能,值得临床推广。
Objective To analyze the effect of atorvastatin calcium in the treatment of chronic heart failure and arrhythmia.Methods 94 patients with chronic heart failure and arrhythmia were selected as the study subjects and divided into a reference group(n=47)and a study group(n=47)according to the odd even principle.The reference group was given amiodarone for treatment,while the study group was given atorvastatin calcium for treatment.Comparison of clinical efficacy,blood pressure[systolic blood pressure(SBP)and diastolic blood pressure(DBP)]levels,blood lipid[high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triglycerides(TG)],cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),and left ventricular end-diastolic diameter(LVEDD)]between the two groups.Results The total effective rate of treatment 97.87%in the study group was significantly higher than 82.98%in the reference group(P<0.05).After treatment,the study group had SBP of(125.27±3.36)mm Hg(1 mm Hg=0.133 kPa),and DBP of(84.32±2.55)mm Hg,which were lower than those of the reference group[(138.78±5.67)and(97.47±3.63)mm Hg](P<0.05).After treatment,the level of HDL-C in the study group was higher than that in the reference group,while the levels of LDL-C,TC and TG were lower than those in the reference group(P<0.05).After treatment,the study group had LVEF of(56.68±4.28)%,LVESD of(42.17±5.45)mm and LVEDD of(50.53±3.85)mm,which were better than those of the reference group[(51.19±4.96)%,(45.95±4.77)mm,and(54.23±4.41)mm](P<0.05).Conclusion Atorvastatin calcium can significantly improve the clinical treatment effect of patients with chronic heart failure and arrhythmia while improving the cardiac function,and is worthy of clinical promotion.
作者
韩永刚
单林
于立涛
HAN Yong-gang;SHAN Lin;YU Li-tao(Department One of Cardiology,Fangzi District People's Hospital,Weifang 261200,China)
出处
《中国实用医药》
2025年第20期102-105,共4页
China Practical Medicine
